Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seeing the value in observational studies

Executive Summary

Safety signals identified in observational studies require confirmation but provide important information about drug use in a real-world setting, according to a pair of opinion pieces in the Nov. 23 issue of the New England Journal of Medicine; both articles addressed Bayer's failure to disclose a large observational study on its drug Trasylol before a recent advisory committee review (1"The Pink Sheet" Oct. 2, 2006, p. 25). "Although observational studies cannot be definitive...they can provide important new safety information that can direct further scientific and regulatory actions - if their findings can be confirmed," Cardio-Renal Drugs Advisory Committee chair William Hiatt (University of Colorado) said. Jerry Avorn (Harvard Medical School) advises care with application of epidemiological research techniques, and argues that transparency of study methods and raw data are critical to interpreting results that are confounded in such uncontrolled studies...

You may also be interested in...



Trasylol Safety Review Raises Questions About Role Of Observational Data

FDA continues to grapple with the relative benefits of observational data and randomized controlled trials to evaluate drug safety

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel